Analysts’ Weekly Ratings Changes for Certara (CERT)

Several analysts have recently updated their ratings and price targets for Certara (NASDAQ: CERT):

• 10/16/2026 – Certara had its price target raised by KeyCorp from $9.00 to $12.00. They now have an “overweight” rating on the stock.
• 10/13/2026 – Certara had its price target raised by TD Cowen from $9.00 to $11.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Certara was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 10/7/2026 – Certara had its price target raised by Barclays from $7.50 to $9.00. They now have an “equal weight” rating on the stock.
• 9/30/2026 – Certara had its “neutral” rating reaffirmed by UBS Group. They now have a $10.00 price target on the stock.

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.